405 related articles for article (PubMed ID: 33856022)
21. Identification of the immune gene expression signature associated with recurrence of high-grade gliomas.
Roura AJ; Gielniewski B; Pilanc P; Szadkowska P; Maleszewska M; Krol SK; Czepko R; Kaspera W; Wojtas B; Kaminska B
J Mol Med (Berl); 2021 Feb; 99(2):241-255. PubMed ID: 33215304
[TBL] [Abstract][Full Text] [Related]
22. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
[TBL] [Abstract][Full Text] [Related]
23. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma.
Foster A; Nigam S; Tatum DS; Raphael I; Xu J; Kumar R; Plakseychuk E; Latoche JD; Vincze S; Li B; Giri R; McCarl LH; Edinger R; Ak M; Peddagangireddy V; Foley LM; Hitchens TK; Colen RR; Pollack IF; Panigrahy A; Magda D; Anderson CJ; Edwards WB; Kohanbash G
EBioMedicine; 2021 Sep; 71():103571. PubMed ID: 34530385
[TBL] [Abstract][Full Text] [Related]
24. The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.
Wang Z; Liu Y; Mo Y; Zhang H; Dai Z; Zhang X; Ye W; Cao H; Liu Z; Cheng Q
Front Immunol; 2021; 12():731751. PubMed ID: 34603309
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
[TBL] [Abstract][Full Text] [Related]
26. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Implications of the Complement Protein C1q in Gliomas.
Mangogna A; Belmonte B; Agostinis C; Zacchi P; Iacopino DG; Martorana A; Rodolico V; Bonazza D; Zanconati F; Kishore U; Bulla R
Front Immunol; 2019; 10():2366. PubMed ID: 31649675
[TBL] [Abstract][Full Text] [Related]
28. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic regulation of tumor-immune symbiosis in glioma.
Liu Y; Ali H; Khan F; Pang L; Chen P
Trends Mol Med; 2024 May; 30(5):429-442. PubMed ID: 38453529
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
[TBL] [Abstract][Full Text] [Related]
32. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
33. Microglia in the Brain Tumor Microenvironment.
Cole AP; Hoffmeyer E; Chetty SL; Cruz-Cruz J; Hamrick F; Youssef O; Cheshier S; Mitra SS
Adv Exp Med Biol; 2020; 1273():197-208. PubMed ID: 33119883
[TBL] [Abstract][Full Text] [Related]
34. Molecular characteristics of pediatric high-grade gliomas.
Chamdine O; Gajjar A
CNS Oncol; 2014 Nov; 3(6):433-43. PubMed ID: 25438814
[TBL] [Abstract][Full Text] [Related]
35. Pediatric low-grade gliomas: how modern biology reshapes the clinical field.
Bergthold G; Bandopadhayay P; Bi WL; Ramkissoon L; Stiles C; Segal RA; Beroukhim R; Ligon KL; Grill J; Kieran MW
Biochim Biophys Acta; 2014 Apr; 1845(2):294-307. PubMed ID: 24589977
[TBL] [Abstract][Full Text] [Related]
36. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
37. Glioma.
Weller M; Wick W; Aldape K; Brada M; Berger M; Pfister SM; Nishikawa R; Rosenthal M; Wen PY; Stupp R; Reifenberger G
Nat Rev Dis Primers; 2015 Jul; 1():15017. PubMed ID: 27188790
[TBL] [Abstract][Full Text] [Related]
38. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment
Zha C; Meng X; Li L; Mi S; Qian D; Li Z; Wu P; Hu S; Zhao S; Cai J; Liu Y
Cancer Biol Med; 2020 Feb; 17(1):154-168. PubMed ID: 32296583
[No Abstract] [Full Text] [Related]
39. Mutational burden and immune recognition of gliomas.
Prost D; Bielle F; Ligon KL; Touat M
Curr Opin Oncol; 2021 Nov; 33(6):626-634. PubMed ID: 34651608
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis.
Zhang L; Zhang B; Dou Z; Wu J; Iranmanesh Y; Jiang B; Sun C; Zhang J
Front Immunol; 2021; 12():582594. PubMed ID: 33815356
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
